Abstract| Volume 83, ISSUE 9, SUPPLEMENT , S305, May 01, 2018

F172. Clinical Evaluation of Abuse Potential of ALKS 5461

      ALKS 5461 is an investigational opioid system modulator for adjunctive treatment of major depressive disorder (MDD) comprised of buprenorphine (BUP) and samidorphan (SAM), a μ-opioid receptor antagonist added to address the abuse/dependence potential of BUP. The ability of SAM to address the abuse potential of BUP in the ALKS 5461 combination was explored.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect